India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd ...

Biocon Ltd expects its overall revenue to grow in mid-teens this financial year, and the company is betting on a robust launch pipeline in its generics as well as biosimilars businesses to drive ...

Biocon's stock saw a price increase of 2.11% to reach Rs 336.80 during today's trading session. This movement is significant as it reflects intraday dynamics and investor response to market ...

May 8, 2025 India's Biocon posts higher quarterly profit on boost from generics, biosimilar business Indian biopharma firm Biocon's profit more than doubled in the fourth quarter, led by strong ...

The Biocon sterile manufacturing plant that got spanked by European and FDA regulators earlier this year has taken another whipping by the FDA, raising new questions about its efforts to get a ...

BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code ...

Biocon in a regulatory filing on Tuesday said it sold 80,00,000 equity shares of its subsidiary Syngene International Ltd. (Syngene) in the open market for Rs.686 crore through a block deal.